Business Context and Reporting Period
This Form 8-K is a current report filed by Magenta Therapeutics, Inc. (not Dianthus Therapeutics, Inc.) on August 5, 2021. The filing primarily announces the company's financial results for the quarter ended June 30, 2021, with the full details provided in an attached press release (Exhibit 99.1). The company is incorporated in Delaware and trades on the Nasdaq Global Market under the symbol MGTA.
Key Financial Metrics
The filing text references the announcement of financial results for the quarter ended June 30, 2021, but does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity within the body of this 8-K document. These figures are contained in the referenced press release (Exhibit 99.1), which is furnished but not included in the provided text.
Material Changes and Corporate Governance
A significant material change involves the departure of a director:
- Resignation: Michael W. Bonney resigned from the Board of Directors and its committees effective August 3, 2021, to focus on his role as Executive Chair of Alnylam Pharmaceuticals, Inc.
- Reason: The resignation was not the result of any dispute or disagreement with the Company.
- Board Adjustments: The Board size was reduced from ten to nine members. Alison F. Lawton was appointed Chair of the Board, and Jeffrey W. Albers was appointed to the audit committee, effective August 4, 2021.
Guidance, Outlook, and Risks
The filing text does not contain specific guidance, outlook, management commentary, or risk factors beyond the standard legal disclaimers. It notes that the information in the 8-K and the attached press release is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference unless expressly stated.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the Press Release dated August 5, 2021), as they are not listed in this summary text.
- Confirm the updated composition of the Board of Directors following the resignation of Michael W. Bonney and the appointment of Alison F. Lawton as Chair.
- Check for any subsequent filings regarding the company's cash runway or capital raise activities, given the lack of specific liquidity data in this report.